Prostate Cancer Radiotherapy Research
The Hopital Prive Clairval Service d’oncologie radiotherapie in Marseille is conducting focused studies on high‑risk localized or locally advanced prostate cancer, evaluating whether adding apalutamide and a GnRH agonist to primary radiation therapy can improve metastasis‑free survival (MFS) as judged by central imaging review.
- Combination systemic therapy with radiation
- Metastasis‑free survival outcomes
- Advanced imaging assessment by BICR
With nine investigators overseeing two active trials, the department emphasizes collaborative, patient‑centered research to enhance treatment effectiveness for prostate cancer patients in Europe.
Innovative Targeted Therapy Trials
A separate study at the same institution evaluates the safety and efficacy of JNJ56021927 (ARN509), a novel androgen‑receptor inhibitor, in patients receiving primary radiation for high‑risk prostate cancer, aiming to improve disease control and reduce side effects.
- Novel androgen‑receptor inhibition
- Safety profiling in a radiotherapy context
- Potential for treatment de‑intensification
Conducted within a non‑commercial hospital setting, this research reflects the site’s commitment to advancing therapeutic options and diagnostic precision for neoplastic diseases.
